Is ritexitinib expensive? Financial burden and alternatives for patients with alopecia areata

Ritlecitinib originally developed by Pfizer, is a new generation of oralJAK3/TEC kinase inhibitor that is highly targeted and has low side effects. It has been approved by regulatory agencies in many countries for the treatment of alopecia areata and other autoimmune diseases. Domestically, ritixitinib has been launched under its original research name or trade name, marking that Chinese patients can also obtain globally synchronized innovative treatment options. Alopecia areata, especially severe alopecia universalis, had limited treatment options in the past. The emergence of ritexitinib has greatly enriched treatment options and brought new hope to this previously neglected patient group.

However, as an innovative drug that has not yet entered the medical insurance catalog, the price of ritexitinib is relatively high. Taking the current mainstream specification in the domestic market as 50mg*30 capsules as an example, the price is usually more than 3,000 yuan per box. In comparison, the price of the overseas European version of the original drug may exceed RMB 10,000 per box (the price may change due to exchange rates) . In addition, generic versions have also appeared in some countries and regions, such as Laos. The ingredients are the same as the original drugs, and the price is more cost-effective. A box costs about 700 yuan, making it one of the overseas purchasing choices for many patients.

In practical applications, ritixitinib has significant efficacy, but its use period is long, which also means that the overall treatment cost cannot be ignored. Since it has not yet been included in China’s medical insurance, the financial burden on ordinary patients is relatively heavy. From the perspective of medical insurance policy, whether this type of drug can quickly enter the national medical insurance negotiation system still needs to observe its future real-world application effects in the country, patient benefit data, and medical insurance affordability and other factors. As market competition intensifies and policy negotiations advance, the availability and price of ritexitinib are expected to be further optimized. Overall, ritexitinib brings new hope to the treatment of alopecia areata. Its value is not only reflected in its efficacy, but also in improving the quality of life of patients.

Reference materials:https://www.litfulo.com/